Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a report released on Monday morning.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $2.32 on Monday. The company has a 50 day moving average price of $2.38 and a 200-day moving average price of $2.38. Oramed Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $3.67. The firm has a market cap of $94.59 million, a price-to-earnings ratio of 4.55 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.21. On average, sell-side analysts anticipate that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ORMP. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Oramed Pharmaceuticals in the 3rd quarter valued at about $272,000. BML Capital Management LLC raised its holdings in shares of Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after acquiring an additional 837,153 shares during the last quarter. Murchinson Ltd. lifted its position in shares of Oramed Pharmaceuticals by 23.2% in the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Oramed Pharmaceuticals in the second quarter worth approximately $40,000. Finally, Renaissance Technologies LLC increased its position in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.